A hypomorphic Artemis human disease allele causes aberrant chromosomal rearrangements and tumorigenesis

Cheryl Jacobs1,†, Ying Huang2,†, Tehmina Masud1,†, William Lu3, Gerwin Westfield2, William Giblin1 and JoAnn M. Sekiguchi1,2,3,*

1Department of Human Genetics, 2Internal Medicine and 3Cellular and Molecular Biology Program, University of Michigan Medical School, Ann Arbor, MI 48109, USA

Received July 26, 2010; Revised and Accepted November 26, 2010

The Artemis gene encodes a DNA nuclease that plays important roles in non-homologous end-joining (NHEJ), a major double-strand break (DSB) repair pathway in mammalian cells. NHEJ factors repair general DSBs as well as programmed breaks generated during the lymphoid-specific DNA rearrangement, V(D)J recombination, which is required for lymphocyte development. Mutations that inactivate Artemis cause a human severe combined immunodeficiency syndrome associated with cellular radiosensitivity. In contrast, hypomorphic Artemis mutations result in combined immunodeficiency syndromes of varying severity, but, in addition, are hypothesized to predispose to lymphoid malignancy. To elucidate the distinct molecular defects caused by hypomorphic compared with inactivating Artemis mutations, we examined tumor predisposition in a mouse model harboring a targeted partial loss-of-function disease allele. We find that, in contrast to Artemis nullizygosity, the hypomorphic mutation leads to increased aberrant intra- and interchromosomal V(D)J joining events. We also observe that dysfunctional Artemis activity combined with p53 inactivation predominantly predisposes to thymic lymphomas harboring clonal translocations distinct from those observed in Artemis nullizygosity. Thus, the Artemis hypomorphic allele results in unique molecular defects, tumor spectrum and oncogenic chromosomal rearrangements. Our findings have significant implications for disease outcomes and treatment of patients with different Artemis mutations.

INTRODUCTION

Artemis (DCLRE1C, DNA crosslink repair 1C, OMIM# 605988) was initially identified as the gene mutated in a human T–B− severe combined immunodeficiency associated with cellular radiosensitivity (RS-SCID) (1–3). Artemis is a DNA nuclease that plays critical roles in the context of the non-homologous end-joining (NHEJ) pathway of DNA double-strand break (DSB) repair (4,5). The NHEJ factors are required for processing and joining chromosomal ends during general DSB repair as well as V(D)J recombination, a lymphoid-specific DNA rearrangement (6). V(D)J recombination is the process by which the vast array of antigen receptor genes are assembled from component V, D and J coding exons. During early lymphocyte development, the RAG1/RAG2 endonuclease generates DSBs at specific recombination signal (RS) sequences that flank the numerous rearranging segments (7–9). Cleavage by RAG1/RAG2 produces two end structures: covalently closed hairpin coding ends and 5′ phosphorylated, blunt RS ends. Prior to ligation, the hairpin coding ends are nicked open by the Artemis endonuclease which is activated upon interaction with the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a central NHEJ factor (4). In the absence of Artemis function, unopened hairpin coding ends accumulate in developing lymphocytes and remain unjoined (10). Thus, mutations that abrogate or reduce Artemis activity result in defective V(D)J recombination and impaired B and T lymphocyte development.
To date, 48 different mutant Artemis alleles have been identified in association with inherited combined immunodeficiency syndromes, including missense, splice-site and nonsense mutations, gross exonic and smaller deletions and a small insertion (2,11). The majority of mutations are located within a region encoding a highly conserved metallo-β-lactamase/BCASP N-terminal domain (aa 1–385). A smaller subset of Artemis alleles resides within a non-conserved C-terminus (aa 386–692), and these mutations are small nucleotide deletions or insertions resulting in frameshifts followed by premature translation termination. Patients harboring null mutations suffer from an absence of B and T lymphocytes, whereas partial loss-of-function Artemis alleles are associated with immunodeficiency syndromes of varying severity, including B<sup>-/-</sup>/low T<sup>-/-</sup> SCID, B<sup>-/-</sup> SCID, chronic inflammatory bowel disease and Omenn syndrome (2,11–24).

The unjoined DNA ends that accumulate in lymphocytes due to defects in the NHEJ pathway can be misrepaired via alternative repair pathways, thereby leading to genome instability and potentially detrimental chromosomal aberrations, including oncogenic translocations (25). In this regard, partial B and T immunodeficiency and aggressive B cell lymphoma was observed in patients harboring a premature translation termination Artemis mutation within exon 14, which encodes the non-conserved C-terminal domain (D451fsX10, referred to as P70, herein) (12). These lymphoid tumors were associated with Epstein-Barr virus (EBV). However, molecular analyses revealed that the lymphomas were of clonal origin, as evidenced by the rearrangement status of the immunoglobulin heavy chain locus, and also harbored chromosomal anomalies and increased genome instability (12). These features suggest that aberrant Artemis activity contributes to oncogenesis; however, it has not yet been established whether hypomorphic Artemis mutations can predispose to tumorigenesis. To date, patients harboring null Artemis alleles have not been reported to exhibit lymphoid malignancies. These findings raise the possibility that partial loss of Artemis alleles that lead to truncation of the non-conserved C-terminus may have greater oncogenic potential compared with complete null alleles.

Artemis forms a complex with DNA-PKcs, a serine–threonine protein kinase, via interactions within the C-terminal domain. The Artemis-DNA-PKcs complex possesses intrinsic endonucleolytic activities that can cleave DNA at single-to-double-strand transitions, including hairpins and 5′ or 3′ overhangs (4,5,26,27), as well as single strands (28). The Artemis C-terminus undergoes extensive phosphorylation by DNA-PKcs (29–31). In vitro biochemical studies with mutant forms of Artemis harboring site-specific mutations revealed that DNA-PKcs-dependent phosphorylation is not required for activation of endonucleolytic activity (29). However, C-terminally truncated forms of Artemis that retain stable interaction with DNA-PKcs but that lack the majority of phosphorylation sites, including the lymphoma-associated Art-P70 protein, exhibit reduced DNA-PKcs-dependent endonucleolytic activity (26,32). In previous studies, we demonstrated that a mouse model harboring the Art-P70 mutation recapitulated the partial B and T immunodeficiency phenotypes observed in patients (32). We determined that lymphocyte development was impaired due to substantially reduced, but not abrogated, hairpin opening activity catalyzed by the Art-P70 mutant protein. Together, these results indicate that the Artemis C-terminal domain plays important roles in modulating biochemical and in vivo Artemis activities, in addition to facilitating DNA-PKcs interaction.

In this study, we examine the impact of the Art-P70 hypomorphic allele on predisposition to tumorigenesis. We observe that loss of a functional region within the non-conserved Artemis C-terminus leads to aberrant intra- and interchromosomal rearrangements within the antigen receptor loci. In addition, we find that the Artemis-P70 allele in the context of p53 inactivation predisposes to a spectrum of B and T lymphoid malignancies that is distinct from that observed in Artemis nullizygosity. The tumors arising in an Art-P70/p53 background are associated with clonal chromosomal translocations involving the rearranging loci due to misrepair of RAG-generated DNA breaks. Together, these findings provide insights into the molecular basis of tumorigenesis associated with defective, but not abrogated, V(D)J recombination activity. In addition, the results uncover potential roles for Artemis function in contributing to DNA end complex stability of RAG1/2-generated chromosomal breaks.

RESULTS

The Artemis-P70 mutation results in elevated interchromosomal V(D)J rearrangements

We previously observed that the Art-P70 homozygous mutation led to an accumulation of hairpin coding ends in developing lymphocytes; however, the levels were notably lower compared with Artemis nullizygosity (32). The presence of coding ends led us to determine whether the unjoined DSB intermediates engage in aberrant chromosomal rearrangements. To this end, we employed a nested polymerase chain reaction (PCR) approach to examine the levels of interchromosomal V(D)J rearrangements between the TCR<sup>b</sup> locus (chr. 6) and TCRγ (chr. 13) loci in Art<sup>P70/P70</sup> and Art<sup>-/-</sup> thymocytes, followed by Southern blot analysis. Interchromosomal transrearrangement is a global predictor of chromosomal translocation (33,34) and occurs at elevated frequencies in lymphocytes harboring mutations in genes that predispose to lymphoid neoplasia, including ATM (35–39), DNA-PKcs (34), Nbs1 (33,38) and 53BP1 (40).

Initially, we examined levels of normal TCRγ V-to-J and TCRβ D-to-J rearrangements by PCR amplification. As previously reported, we observed that TCRβ D-to-J rearrangements in Art<sup>P70/P70</sup> thymocytes were reduced and were not readily detected in Art<sup>-/-</sup> thymocytes (10,32) (Fig. 1A). In comparison, products corresponding to TCRγ intrachromosomal V-to-J and TCRγ D-to-J rearrangements were not significantly decreased in Art<sup>P70/P70</sup> and Art<sup>-/-</sup> thymocytes compared with controls. These findings indicate that the Artemis P70 and null mutations impair rearrangement at the TCRγ locus to a lesser extent compared with TCRβ rearrangements, as has been observed at the TCRδ locus in NHEJ-deficient backgrounds, including Artemis nullizygosity (41–44).

Next, we determined whether transrearrangement occurs between loci on different chromosomes using PCR primers
located upstream of TCRγV3S1 and downstream of TCRβJ2. As anticipated, we detected robust levels of transrearrangement between TCRγ and TCRβ in ATM null thymocytes (35–39). PCR products corresponding to interchromosomal V(DJ) rearrangements in wild-type or p53−/− thymocytes were not readily observed, as previously reported (33,38,45) (Fig. 1A). Similar to ATM−/− lymphocytes, we detected substantially increased levels of interchromosomal events involving TCRγV3S1 and TCRβJ2 in ArtP70/P70 thymocytes (n = 5) compared with controls, despite harboring lower levels of Dβ2-to-Jβ2 intrachromosomal rearrangements (Fig. 1A, data not shown). On the contrary, we observed a lower frequency of transrearrangement in Art−/− thymocytes. In this regard, two of seven Artemis null mice harbored PCR products corresponding to TCRγ-to-TCRβ interchromosomal rearrangements (Fig. 1A, data not shown), and the events appeared to be clonal as only a single band was observed, compared with multiple bands observed in ArtP70/P70 and ATM−/− thymocytes. Thus, the Art-P70 mutation increases the propensity of unjoined coding ends to engage in aberrant interchromosomal translocations involving rearranging V(DJ) loci. Moreover, this phenotype is distinct from that observed in Artemis null thymocytes which exhibit infrequent transrearrangements despite harboring a higher level of unjoined hairpin coding ends.

We next examined the frequency of interchromosomal rearrangements in Art-P70 heterozygous thymocytes to determine whether the hypomorphic mutation results in a dominant...
phenotype. TCRγV3S1 to TCRβJ2 transrearrangements were readily detected in Art+/P70 thymocytes in more than half (six of ten) of the mice examined (Fig. 1B). However, fewer PCR products corresponding to distinct rearrangements and lower levels of interchromosomal events were observed in Art+/P70 compared with ArtP70/P70 and ATM−/− thymocytes. The levels of TCRβ D-to-J rearrangements in Art-P70 heterozygous thymocytes were similar to those observed in wild-type controls (Fig. 1B). These findings indicate that the C-terminally truncated Art-P70 protein does not substantially disrupt proper coding end processing and joining, yet increases chromosomal anomalies, even when the wild-type enzyme is present.

The nested PCR products from Art-P70 mutant thymocytes were cloned and sequenced in order to verify that they represent the predicted interchromosomal events. We obtained several unique clones from four ArtP70/P70 mice containing flanking sequence from TCRγV3S1 and TCRβJ2, thereby indicating that the PCR primers indeed amplified V(D)J transrearrangements (Fig. 1C). The junctions contained non-templated (N) and palindromic (P) nucleotides and small deletions, similar to the coding joints analyzed from intrachromosomal V(D)J recombination events in the ArtP70/P70 mice (32). We also cloned and sequenced the PCR products corresponding to the interchromosomal rearrangements obtained from Art−/− thymocytes. Sequencing of multiple clones yielded one unique sequence, thereby indicating that the single PCR product likely represents a clonal event (Fig. 1C). These results support the notion that aberrant end processing due to the hypomorphic Art-P70 mutation generates V(D)J ends that engage in chromosomal translocations at an elevated frequency compared with a complete absence of Artemis.

The Artemis-P70 mutation results in increased deletional chromosomal hybrid joining

Hybrid joint formation occurs between a coding and an RS end and represents an unproductive V(D)J rearrangement. Inversional chromosomal rearrangements require that the two coding and two RS ends generated by the RAG endonuclease are maintained in proximity in order to facilitate coordinated processing and ligation. Increased levels of deletional chromosomal hybrid joining during inversional V(D)J rearrangement are hypothesized to result from inappropriate release of RAG-generated ends from DNA end complexes, thereby leading to

Figure 2. Deletional hybrid joint formation in Art-P70 mutant lymphocytes. (A) Left panel: Schematic representation of nested PCR strategy for detecting coding and hybrid joints within the IgLκ locus. Relative orientation of Vβ6-23 and Jζ1 coding (rectangles) and RSSs (triangles) within the IgLκ locus. Inversional (CJ) and deletional (HJ) products are depicted. Positions of primers (I = pβa, A = pζ1a, B = pζ6b, C = pζ6c, D = pζ6d) and probe (P) are shown. Right panel: PCR analysis of Vβ6-23 to Jζ1 coding joints (CJs) and hybrid joints (HJs). Genomic splenocyte DNA was isolated from WT, ATM−/−, Art−/− and ArtP70/P70 mice and amplified using primers (pζa and pζ6d for CJ and pζa and pζ6a for HJ). Serial 4-fold dilutions of the PCR reaction were amplified using nested primer pairs (pζa and pζ6c for CJ, and pζa and pζ6b for HJ). CJ and HJ bands are 0.6 and 0.25 kb, respectively.

(B) Deletional hybrid joining and coding joining within the TCRβ locus. Upper panel: Schematic of nested PCR strategy. Relative orientation of Vβ14, DJ2 and Jβ2.3 coding (rectangles) and RSSs (triangles) within the TCRβ locus. Positions of primers (I = pβa, II = pβb, III = pβc, IV = pβd, V = pβe, VI = pβf) and probe (P = pβg) are shown. Lower panel: PCR analysis of Vβ14 to Jβ2 coding and hybrid joints. Left panel shows CJ and HJ PCR analyses of genomic thymocyte DNA isolated from WT, ATM−/−, Art−/− and ArtP70/P70 mice. Right panel shows CJ and HJ PCR analyses of ArtP70 and control thymocyte genomic DNA, as indicated. Primers for CJ were pβc and pβf. Primary primers for HJ were pβa and pβb. Serial 4-fold dilutions of this primary HJ reaction were amplified using primers pβc and pβd. CJ and HJ bands are 0.3 and 0.9 kb, respectively. PCR amplification of a non-rearranging locus was performed to normalize the input genomic DNA. Representative results are shown.
the loss of the intervening genomic fragment (41,46,47). Our observations of increased interchromosomal rearrangements in ArtP70/P70, but not Art2/2 lymphocytes, led us to examine the frequency of deletional hybrid joining in these mutant backgrounds. To this end, we examined hybrid joint formation during IgL-κ locus rearrangements in splenocytes. Productive rearrangement between Vκ and Jκ segments occurs via inversion; thus, hybrid joining results in deletion of the intervening DNA segment (Fig. 2A).

Using a nested PCR approach, we readily detected Vκ to Jκ hybrid joints in ArtP70/P70 splenocytes in the majority (three of four) of mutant mice analyzed (Fig. 2A). The levels were lower than those observed in ATM deficiency, but markedly higher compared with wild-type or Art2/2 splenocytes. We also observed decreased levels of Vκ to Jκ coding joining in Art-P70 mutant splenocytes compared with controls; therefore, the relative frequency of deletional hybrid joining compared with inversional coding joining within the IgLκ locus is substantially increased by the Art-P70 mutation.

Within the TCRβ locus, VB14-to-DJβ2 rearrangements also occur via inversion; thus, we examined deletional hybrid joining between VB14 and DJβ2 via nested PCR. We detected increased levels of VB14–DJβ2 hybrid joints in ArtP70/P70 thymocytes (two of four), albeit at lower levels compared with ATM deficiency (Fig. 2B). Hybrid joints were not detected in Art−/− thymocytes, as previously reported (47) (Fig. 2B). Given our findings that interchromosomal rearrangements were detected in ArtP70 thymocytes, we assessed the impact of Art-P70 heterozygosity on VB14–DJβ2 hybrid joining (Fig. 2B). We also detected hybrid joints in a subset of Art+/P70 mice examined (two of five), thereby providing additional evidence that the Art-P70 allele may have a dominant effect in promoting aberrant rearrangements.

Examination of ATM- and MRN-dependent DNA damage responses in Artemis-P70 cells

The increased levels of interchromosomal rearrangements and deletional hybrid joining observed in ArtP70/P70 lymphocytes parallel the phenotypes observed in ATM, Mre11 and Nbs1 mutant lymphocytes (41,46,47). These findings raise the possibility that the Art-P70 allele impairs ATM-dependent responses to DNA DSBs and/or disrupts the functional Mre11/Rad50/Nbs1 (MRN) complex. To address these questions, we examined key ATM-dependent cellular responses to ionizing radiation (IR)-induced DSBs in ArtP70/P70 murine...
embryonic fibroblasts (MEFs). Upon exposure to IR, the ATM protein kinase undergoes autophosphorylation in an MRN-dependent manner (48,49) and subsequently phosphorylates downstream targets, including the histone variant, H2AX (38,50) and the transcriptional corepressor, KAP1 (51). We examined the levels of phospho-ATM (p-ATM), phospho-H2AX (γH2AX) and phospho-KAP-1 (p-KAP1) in Art<sup>P70/P70</sup>, Art<sup>−/−</sup> and wild-type MEFs at 1 h post-irradiation by western blotting. We observed similar levels of IR-induced phosphorylation of ATM, H2AX and KAP-1 in Art<sup>P70/P70</sup> and Art<sup>−/−</sup> cells (Fig. 3A). These findings indicate that the Art-P70 and null alleles do not significantly impair ATM-dependent responses to DSBs.

We next assessed the impact of the Art-P70 allele on the stability and localization of the MRN complex. We examined the levels of Mre11, Rad50 and Nbs1 in whole-cell lysates and upon immunoprecipitation of the complex using anti-Mre11 antibodies in Art<sup>P70/P70</sup> MEFs and wild-type controls by western blotting. We observed that the overall levels of Mre11, Rad50 and Nbs1 in Art<sup>P70/P70</sup> MEFs were not different from those observed in control cells (Fig. 3B). Furthermore, we observed similar levels of Mre11, Rad50 and Nbs1 upon co-immunoprecipitation of Mre11 from Art<sup>P70/P70</sup> and wild-type cells, thereby indicating that the MRN complex was not disrupted by the Art-P70 allele (Fig. 3B).

During repair of IR-induced DSBs, Mre11 localizes to sites of damage and forms repair foci that can be visualized as punctate staining by immunofluorescence (48,52). DNA damage-induced Mre11 foci formation requires the presence of an intact and functional MRN complex (48). We exposed Art<sup>P70/P70</sup>, Art<sup>−/−</sup> and wild-type MEFs to IR and quantitated the number of untreated and irradiated cells containing Mre11 foci. We observed that the Art-P70 and Art null alleles did not reduce IR-induced Mre11 foci formation (Fig. 3C). These results indicate that the Art-P70 mutation does not impair ATM- and MRN-dependent DNA damage responses. Thus, these findings are consistent with the notion that the aberrant rearrangements observed in Art<sup>P70/P70</sup> lymphocytes are due to defects in Artemis function at RAG-generated DSBs.

**Artemis-P70 predisposes to lymphoma in a p53 mutant background**

The increased levels of aberrant rearrangements in Art<sup>P70/P70</sup> lymphocytes suggested that the Art-P70 mutation may increase the frequency of RAG-generated DNA ends that engage in oncogenic translocations. To address this question, we examined cohorts of Art<sup>P70/P70</sup>, Art<sup>−/−</sup> and wild-type mice over a period of 12 months to determine whether the Art-P70 mutation predisposes to lymphoid or other tumors. We observed that two of fourteen Art<sup>P70/P70</sup> mice became moribund at 7 and 9 months of age as a result of large thymic masses (Fig. 4A). Flow cytometric analyses revealed that the thymic lymphomas were primarily of a CD4<sup>+</sup>CD8<sup>+</sup> TCRβ<sup>+</sup> origin (Fig. 4B). In comparison, the wild-type and Art<sup>−/−</sup> control cohorts survived tumor-free within the 12-month period, which is consistent with previous reports (53,54).

To further assess the oncogenic potential of the Art-P70 hypomorphic allele, we examined the impact of p53 mutation on tumor predisposition through mouse breeding. The experimental cohorts were on a closely matched 129Sv/C57Bl6 background, thereby minimizing potential strain background effects. However, a subtle impact of genetic background cannot be entirely ruled out. Inactivation of the p53-dependent cell-cycle checkpoint in Artemis mutant lymphocytes allows cells harboring unrepaired DSBs or activated oncogenes to survive (13 weeks) was similar to that observed for Art-P70/p53 double null mice (54,59). We observed that Art-P70/p53 double mutant mice exhibit significantly decreased survival compared with p53<sup>−/−</sup> controls (median survival of 11 and 18 weeks, respectively; \( P = 0.001 \); Fig. 4A). As previously reported, we found that Art<sup>−/−</sup>p53<sup>−/−</sup> mice also exhibited decreased survival compared with p53 null controls, and the median survival (13 weeks) was similar to that observed for Art-P70/p53 double-deficient cohort (Fig. 4A). We found that the Art<sup>−/−</sup>p53<sup>−/−</sup> and Art<sup>P70/P70</sup>p53<sup>−/−</sup> mice succumbed to lymphoid tumors. Flow cytometric analysis of the tumors revealed that Art<sup>−/−</sup>p53<sup>−/−</sup> mice were predominantly predisposed to disseminated B220<sup>+</sup>CD43<sup>+</sup> IgM<sup>+</sup> pro-B lymphomas, as has been previously reported (54) (Fig. 4B). In contrast, the majority of tumors that arose in the Art-P70/p53 double-deficient background were CD4<sup>+</sup>CD8<sup>+</sup> TCRβ<sup>+</sup> thymic lymphomas (Fig. 4B). B220<sup>+</sup>CD43<sup>+</sup> IgM<sup>+</sup> pro-B lymphomas were also observed in Art<sup>P70/P70</sup>p53<sup>−/−</sup> mice, similar to Art/p53 double null mice (54) (Fig. 4B), albeit at a significantly lower frequency (\( P = 0.014 \); two-tailed Fisher’s exact test). These findings indicate that the Art-P70 allele predisposes to lymphoid malignancies in a p53-deficient background, and the lymphoma spectrum observed in Art<sup>P70/P70</sup>p53<sup>−/−</sup> mice is distinct from that observed in NHEJ/p53 double null backgrounds, including Art<sup>−/−</sup>p53<sup>−/−</sup> mice (54,59).
Distinct chromosomal anomalies associated with Art-P70/p53 lymphoid tumors

We next examined the status of the rearranging TCRβ and IgH loci in the lymphomas that arose in the Art-P70/P70p53−/− mice. Genomic DNA isolated from Art-P70/P70p53−/− tumors was digested with EcoRI and analyzed by Southern blotting. Individual tumors are indicated (top). Thymus, kidney and bone marrow (BM), control tissues; GL, unrearranged, germline band. Amounts of input DNA were normalized to a non-rearranging locus (LR8). *-pro-B lymphomas (C219, C263, C318). (B) Analysis of Art-P70/p53 pro-B lymphomas by Southern blotting. Genomic DNA isolated from Art-P70/p53 double-mutant lymphomas was digested with EcoRI and then analyzed by Southern blotting. Previously characterized probes that hybridized to the JH, Cμ and HS3A regions of the IgH locus, N-myc on chr. 12 and c-myc on chr. 15 were used, as indicated. Individual tumors are indicated, top; thymus, kidney, and bone marrow (BM), control tissues; GL, unrearranged, germline band. Amounts of input DNA were normalized to a non-rearranging locus (LR8). Fold amplification compared with the non-rearranging locus was calculated as described in Materials and methods. (C) Semi-quantitative RT-PCR of N-myc and c-myc transcript levels. Total RNA was isolated from primary tumor cells, and RT-PCR was performed. cDNAs were PCR amplified using N-myc (exons 2 and 3), c-myc (exons 1−3) and tubulin-specific primers. Tumor numbers, as indicated; C, total RNA from normal, wild-type LN; −, no-RT control. Art-P70/p53−/− tumors: thymic lymphomas: C227, C262, C306, C311, C322, C324, C325, C267, C268; pro-B lymphomas: C219, C263, C318. Art−/−p53−/−; pro-B lymphoma: C405.

Figure 5. Clonal rearrangements involving recombining loci in Art-P70/p53 tumors. (A) Analysis of TCR rearrangement status in Art-P70/p53 thymic lymphomas. Genomic DNA isolated from ArtP70/P70p53−/− tumors was digested with EcoRI and then analyzed by Southern blotting. Individual tumors are indicated (top). Thymus, kidney and bone marrow (BM), control tissues; GL, unrearranged, germline band. Amounts of input DNA were normalized to a non-rearranging locus (LR8). *-pro-B lymphomas (C219, C263, C318). (B) Analysis of Art-P70/p53 pro-B lymphomas by Southern blotting. Genomic DNA isolated from Art-P70/p53 double-mutant lymphomas was digested with EcoRI and then analyzed by Southern blotting. Previously characterized probes that hybridized to the JH, Cμ and HS3A regions of the IgH locus, N-myc on chr. 12 and c-myc on chr. 15 were used, as indicated. Individual tumors are indicated, top; thymus, kidney, and bone marrow (BM), control tissues; GL, unrearranged, germline band. Amounts of input DNA were normalized to a non-rearranging locus (LR8). Fold amplification compared with the non-rearranging locus was calculated as described in Materials and methods. (C) Semi-quantitative RT-PCR of N-myc and c-myc transcript levels. Total RNA was isolated from primary tumor cells, and RT-PCR was performed. cDNAs were PCR amplified using N-myc (exons 2 and 3), c-myc (exons 1−3) and tubulin-specific primers. Tumor numbers, as indicated; C, total RNA from normal, wild-type LN; −, no-RT control. Art-P70/p53−/− tumors: thymic lymphomas: C227, C262, C306, C311, C322, C324, C325, C267, C268; pro-B lymphomas: C219, C263, C318. Art−/−p53−/−; pro-B lymphoma: C405.

Distinct chromosomal anomalies associated with Art-P70/p53 lymphoid tumors

We next examined the status of the rearranging TCRβ and IgH loci that arose in the Art-P70/P70p53−/− and Art-P70/P70 mice. Genomic DNA isolated from the primary tumors was digested with EcoRI and analyzed by Southern blotting. We used a probe located within the TCR Dβ1 to Jβ1 region to examine rearrangement status of the TCRβ locus. We observed that the Art-P70/P70p53−/− thymic tumors exhibited clonal rearrangements on one or both alleles, as evidenced by hybridization of specific bands that are distinct from the germline, unrearranged band or deletion of the hybridizing region (Fig. 5A). Similarly, the two Art-P70/P70p53−/− tumors exhibited clonal DJβ rearrangements (data not shown). These results indicate that the thymic lymphomas emanated from a clonal event within the population of developing Art-P70 mutant thymocytes.

We also analyzed the rearrangement status of the IgH locus in Art-P70/p53 pro-B lymphomas by Southern blotting. Genomic DNA isolated from primary tumors was digested with EcoRI and analyzed by Southern blotting. We previously characterized probes that hybridized to the JH, Cμ and HS3A regions of the IgH locus, N-myc on chr. 12 and c-myc on chr. 15 were used, as indicated. Individual tumors are indicated, top; thymus, kidney, and bone marrow (BM), control tissues; GL, unrearranged, germline band. Amounts of input DNA were normalized to a non-rearranging locus (LR8). Fold amplification compared with the non-rearranging locus was calculated as described in Materials and methods. (C) Semi-quantitative RT-PCR of N-myc and c-myc transcript levels. Total RNA was isolated from primary tumor cells, and RT-PCR was performed. cDNAs were PCR amplified using N-myc (exons 2 and 3), c-myc (exons 1−3) and tubulin-specific primers. Tumor numbers, as indicated; C, total RNA from normal, wild-type LN; −, no-RT control. Art-P70/p53−/− tumors: thymic lymphomas: C227, C262, C306, C311, C322, C324, C325, C267, C268; pro-B lymphomas: C219, C263, C318. Art−/−p53−/−; pro-B lymphoma: C405.

We next analyzed the status of the c-myc and N-myc loci, as amplification of either genomic region is associated with Art−/−p53−/− pro-B tumors. Southern blotting revealed genomic amplification of the N-myc locus in tumor C263 (Fig. 5B), and we determined that N-myc expression was elevated by northern blot and semi-quantitative RT-PCR analyses (Fig. 5C, data not shown). Thus, this Art-P70/p53−/− pro-B lymphoma harbors the established hallmark events observed in Art/p53 double-mutant tumors, i.e. increased copy number of the IgH and N-myc genomic loci. However, we did not...
observe genomic amplification of either c-myc or N-myc in the C219 and C318 ArtP70/P70p53−/− pro-B tumors, providing further distinction between lymphomas arising in the Art-P70 versus null backgrounds.

Spectral karyotyping and fluorescence in situ hybridization analyses of Art-P70/p53 double-mutant lymphomas

We next examined the cytogenetic events occurring in Art-P70/p53 double-mutant lymphomas using spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) analyses. We performed SKY on metaphase spreads from seven ArtP70/P70p53−/− thymic lymphomas. We observed that all of the Art-P70/p53 tumors analyzed contained non-reciprocal clonal translocations involving chromosomes harboring rearranging loci (Fig. 6A and B). In this regard, five tumors harbored clonal events involving chr. 14, the location of the TCRα6 locus, translocated to chr. 1, 2, 4 or 12 (Fig. 6A). It is of interest to note that the IgH locus is located on chr. 12, and in addition to the t(12;14) translocation in tumor C306, we also observed t(12;11) and t(12;1) clonal events in tumors C262 and C268, respectively. One tumor, C227, also harbored clonal events involving chr. 13 (TCRβ) translocated to chr. 6 (TCRδ) (Fig. 6A and B). We analyzed one ArtP70/P70p53−/− pro-B lymphoma, C219, by SKY and observed that, similar to other reported NHEJ/p53 double null tumors, it harbored a t(12;15) non-reciprocal translocation (Fig. 6A).

Figure 6. Art-P70/p53 tumors harbor clonal chromosomal translocations. (A) Table summarizing clonal translocations observed in Art-P70/p53 tumors. Metaphases from primary tumor cells or early passage tumor cell cultures were analyzed by SKY. At least 10 metaphases from each tumor were scored. (B) SKY images of metaphase chromosomes from Art-P70/p53 tumors. DAPI staining (left panels) and SKY analysis (right panels) of tumor C325 and C227 containing clonal t(4;14) and t(6;13) translocations, respectively. Arrows indicate translocated chromosomes. (C) FISH analyses of metaphases from Art-P70/p53 tumors. Representative FISH analyses of metaphases from Art-P70/p53 tumors. Left panel, pro-B lymphoma, C219. Left panel, thymic tumor C306. At least 20 metaphases were scored for each tumor. Diagrams indicate the relative chromosomal positions and fluorescent colors of BAC probes. Inset, enlarged images of co-localized probes.
SKY analyses can effectively identify gross chromosomal anomalies; however, genomic loci that may be amplified or co-localized cannot be accurately detected using this technique. Thus, we further analyzed the metaphases from Art-P70/p53 lymphomas using a two-color FISH approach. We established that thymic lymphomas, C325 and C306, harbored clonal chr. 14 anomalies using bacterial artificial chromosome (BAC) probes comprised of genomic sequences located upstream and downstream of the rearranging TCRαβ locus. In this regard, we observed co-localization of the probes in control metaphases, whereas the two probes were clearly located on different chromosomes in metaphases from the ArtP70/P70p53−/− thymic tumors (Supplementary Material, Fig. S1). In tumor C306, we also observed co-localization of the IgH and TCRαβ BAC probes, as anticipated based on the t(12;14) identified by SKY (Fig. 6C). Likewise, we found co-localization of BAC probes containing TCRβ and TCRγ genomic sequences in tumor C227. Tumor C262 harbored separated single-copy FISH signals using BACs located upstream and downstream of the IgH locus on chr. 12 (Supplementary Material, Fig. S1). Thus, the ArtP70/P70p53−/− thymic lymphomas harbored chromosomal aberrations and translocation events that involved the loci undergoing V(DJ) recombination. However, we did not observe amplification of the rearranging loci examined in the thymic lymphomas (Fig. 6C and Supplementary Material, Fig. S1).

FISH analyses of metaphases from Art-P70/p53 pro-B lymphoma, C219, revealed separation of single-copy signals using the upstream and downstream IgH probes, thereby suggesting that RAG-generated DSBs within the rearranging locus initiated the aberrant events (Supplementary Material, Fig. S1). We also observed co-localization of the FISH signals corresponding to c-myc (chr. 15) and IgH loci, as predicted based on the SKY results. However, distinct from the hallmark amplification observed in other NHEJ/p53 double null pro-B tumors, no amplification of either signal was found (Fig. 6C). These findings are consistent with the Southern blot analyses that did not detect amplification using probes within the c-myc, JH, Cκ or HS3A loci.

Previous studies of other NHEJ/p53 double null pro-B lymphomas, including Art−−/−p53−/− tumors, established that genomic amplification of the c-myc locus was associated with elevated c-myc expression levels in the tumor cells (54,59). As we did not observe amplification of c-myc by Southern or FISH analyses, we sought to determine whether the oncogene may be dysregulated by a distinct mechanism in the ArtP70/P70p53−/− tumor, C219, which harbored the t(12;15) translocation and co-localization of c-myc and IgH FISH probes. Thus, we examined expression levels of c-myc in primary tumor cells compared with control cells by semi-quantitative RT-PCR (Fig. 5C). We observed a substantial increase in c-myc expression in the C219 Art-P70/p53 pro-B lymphoma, comparable to that observed in a control Art−−/−p53−/− tumor (C405) which harbored the hallmark c-myc and IgH amplicon (Fig. 5C and Supplementary Material, Fig. S1). These results suggest that elevated c-myc expression observed in the Art-P70/p53 mutant background results from a mechanism independent of genomic amplification and thus distinct from that observed in Art−−/−p53−/− tumors.

**DISCUSSION**

In this study, we demonstrate that a hypomorphic *Artemis* mutation that results in partial B and T immunodeficiency and EBV-associated lymphoma in patients increases the frequency of aberrant chromosomal rearrangements in primary lymphocytes and predisposes to lymphoid malignancy in a mouse model harboring the human disease allele. The Art-P70 mutation, which truncates the non-conserved C-terminus, results in elevated levels of V(DJ) transarrangements between loci located on different chromosomes and deletional hybrid joining in homozygous and heterozygous mutant lymphocytes. In comparison, undetectable or substantially lower levels of these chromosomal anomalies are present in Artemis null lymphocytes, thereby indicating that loss of functional regions within the C-terminal domain increases the potential for the DSB intermediates to engage in aberrant repair events.

Previously, we demonstrated that a mutant Artemis protein modeled after the P70 allele, Art-D451X, interacted stably with DNA-PKcs and exhibited reduced DNA-PKcs-dependent endonucleolytic activity (32). In addition, we found that loss of the C-terminal 241 amino acids markedly reduced DNA-PKcs-dependent phosphorylation due to deletion of the majority of phosphorylation sites. We hypothesized that these defects may impair the ability of Artemis to associate with and properly act upon DNA ends. Consistent with this notion, hairpin coding ends accumulate in ArtP70/P70 developing lymphocytes, whereas nicked hairpins with blunt or 5′ or 3′ overhanging ends are not detected (32). In the current study, we observed increased levels of interchromosomal V(DJ) rearrangements and deletional hybrid joints within the IgLκ and TCRβ loci in ArtP70/P70 primary lymphocytes. The mechanism underlying these events presumably involves inappropriate release of RAG-generated DNA ends from post-cleavage complexes prior to joining (41,46,47). In contrast, these aberrant rearrangements occur infrequently in Artemis null lymphocytes (Figs 1 and 2) (60), despite harboring significantly higher levels of hairpin coding ends compared with Art-P70 mutant lymphocytes (32). Although open hairpins are not detected in ArtP70/P70 lymphocytes, it is possible that a low level of nicked coding ends is present, and these end structures may be more likely to engage in aberrant events. However, interchromosomal rearrangements and deletional hybrid joining occur infrequently in wild-type lymphocytes in which hairpins are efficiently cleaved by Artemis. Likewise, coding ends in normal lymphocytes rarely serve as substrates for oncogenic translocations, even in a p53-deficient background which permits RAG-generated ends to persist throughout the cell cycle (45,54,55,61–66). Thus, the Art-P70 allele likely causes molecular defects in coding end processing and joining beyond impaired hairpin nicking.

Mutations in *ATM*, *Mre11* or *Nbs1* significantly increase the frequency of aberrant chromosomal rearrangements in mutant lymphocytes, including interchromosomal transarrangements and deletional hybrid joint formation (33,35–39, 41,46,47). These observations led to the hypothesis that the ATM kinase and MRN complex function during V(DJ) recombination to enhance DNA end complex stability and promote proper joining of RAG-generated breaks (41,46,47). Our
findings suggest that truncation of the C-terminus impairs functions of Artemis within post-cleavage DNA end complexes, thereby leading to inappropriate release and altered handling of V(D)J recombination intermediates. It is of interest to note that ATM phosphorylates Artemis at residues S503, S516 and S645 which are located within the C-terminal region that is deleted in the Art-P70 mutant protein (29). ATM does not play a direct role in V(D)J recombination per se as ATM-deficient cells exhibit wild-type levels of V(D)J recombination on extra-chromosomal plasmid substrates (67). However, ATM deficiency in mice leads to accumulation of V(D)J coding end intermediates, impaired lymphocyte development and aberrant, potentially oncogenic, chromosomal rearrangements (39,68–72). Although ATM-dependent phosphorylation of Artemis is not required to activate intrinsic endonucleolytic activity in vitro nor is it required for V(D)J recombination on model plasmid substrates in cells (29), our findings raise the possibility that ATM phosphorylation may modulate Artemis functions during chromosomal V(D)J rearrangements to facilitate the stabilization of DNA end complexes in vivo.

We propose that the Art-P70 mutant protein is recruited to DNA ends via interaction with DNA-PKcs (32), and activation of DNA-PKcs upon autophosphorylation induces large conformational changes to allow the nuclease access to the hairpins (29,73,74). Truncation of the Artemis C-terminal region that contains both ATM and DNA-PKcs phosphorylation sites may prevent stable association within conformationally altered DNA end complexes that are poised for further end processing events. Inappropriate release of the RAG-generated ends from aborted post-cleavage complexes would render the ends more susceptible to misrepair, thereby increasing their potential to generate chromosomal aberrations, including oncogenic translocations (41).

We demonstrate that the Art-P70 mutation in a p53 null background accelerates the timing of tumor onset compared with p53 mutation alone. Art-P70/p53 double mutant mice predominantly succumb to CD4+CD8−TCRβ− thymic lymphomas that are associated with clonal chromosomal translocations involving the TCR or IgH loci; however, the majority of tumors do not harbor the hallmark gene amplification events observed in NHEJ/p53 double null lymphomas, including those arising in Art−/−p53−/− mice (54,59,75). We found that the Art−/−p53−/− and Art−/−p53+/− lymphomas arise with a similar latency, despite our observation of substantially higher levels of aberrant interchromosomal rearrangements in Art-P70 mutant lymphocytes. One potential explanation for these observations is that the timing of lymphoma incidence is influenced by the particular oncogenic events associated with tumorigenesis. In this regard, genomic amplification leading to elevated expression of c-myc or N-myc in Art−−p53−/− lymphomas may lead to a higher proliferative potential compared with oncogenic events in the Art−/−p53−/− background, thereby accelerating tumorigenesis in Art/p53 double null mice.

The frequently arising Art−/−p53−/− thymic lymphomas are associated with clonal translocations involving chr. 6, 12, 13 and 14 which harbor the murine TCRB, IgH, TCRγ and TCRα/β loci, respectively, with chr. 14 translocations observed in the majority of the tumors analyzed. Cytogenetic analyses of activated T cells isolated from human lymphoma patients harboring the hypomorphic allele modeled in the Art-P70 mouse and a similar C-terminal truncating mutation (T432SfsX16) revealed a translocation of chr. 7 and 14 and inversion of chr. 7, respectively (12). In humans, the rearranging IgH and TCRα/β loci reside on chr. 14, whereas TCRγ and TCRβ reside on chr. 7. Thus, Art-P70 hypomorphic allele results in translocations involving chromosomes that undergo V(D)J recombination in both human and murine lymphocytes.

The precise mechanisms underlying the distinct molecular events observed in Art-P70/p53 lymphomas have not yet been elucidated. Inactivation of the p53-dependent cell-cycle checkpoint has been hypothesized to allow unrepaired RAG-induced DNA ends generated during G1 to persist throughout the cell cycle and undergo mis-repair by alternative DSB repair pathways (55,59,75). We speculate that unjoined coding ends in Art-P70 versus Artemis null lymphocytes may be repaired by distinct pathways that function during different cell-cycle phases. Consistent with this notion, the junctional sequences of both intra- and interchromosomal V(D)J rearrangements in Art−/−p53−/− lymphocytes are characteristic of joining mediated by the classical NHEJ pathway (32) (Fig. 1). In comparison, an alternative pathway generates aberrant V(D)J junctions containing large deletions and long P nucleotide additions in Art−/− lymphocytes (10) and microhomology mediated translocations in Art−−p53−/− lymphomas (34). An alternative, though not mutually exclusive, hypothesis is that defects in DNA end complex stability in Art-P70 mutant lymphocytes allow unrepaird breaks to be aberrantly localized in three-dimensional space and engage in translocations that do not require the chromosomal partner to be located in proximity. In this regard, recent studies have provided evidence that loci involved in recurrent oncogenic translocations are located in proximity in lymphocytes (76–79). This hypothesis does not preclude amplification from occurring in the Art-P70 background, and indeed we did observe N-myc amplification in one Art−/−p53−/− pro-B lymphoma (C263). It will be of significant interest to further define the molecular mechanisms underlying the oncogenic translocations in Art-P70/p53 tumors.

Together, these studies provide insight into the consequence of truncation of the Artemis C-terminal domain on the fate of chromosomal DNA ends during endogenous V(DJ) rearrangements. Our findings support the notion that loss of the Artemis C-terminus impacts the proper processing and joining of DNA ends via destabilization of end bound complexes that coordinate recombination events. These findings have important clinical implications in the identification and treatment of human immunodeficiency patients harboring similar Artemis mutations that may predispose to aberrant rearrangements and lymphoid malignancy.

**MATERIALS AND METHODS**

**Mice**

Gene-targeted ATM null, Artemis null and Art-P70 mice (mixed 129Sve/C57Bl6 genetic background) were previously generated (10,32,80,81). p53 mutant mice (Trp53tm1Tyj) in a 129S2/Sv background were obtained from Jackson Laboratory
and bred with Art−/− and ArtP70/P70 animals. Double heterozygous Art−/−/p53−/− and Art−/+/p53−/− mice were subsequently interbred to generate progeny of the desired genotypes for the tumorigenesis studies (i.e. Art−/+p53−/−, Art−−/p53−/−, Art−−/p53−/−, Art−−/p53−/−, Art−−/p53−/−, and Art−+/p53−/−). The single- and double-mutant mice as well as wild-type controls used in this study were approximately 75% 129Sv and 25% C57Bl/6; thus, the experimental cohorts are closely strain matched. Mice were housed in a specific pathogen-free facility in a room dedicated to immunocompromised animals.

**Interchromosomal V(D)J rearrangements**

Nested PCR amplification reactions used to detect TCRγ intrachromosomal and TCRγ-to-TCRβ interchromosomal transrearrangements were modified from methods described previously (34). Genomic DNA (100 ng) obtained from thymocytes isolated from 4- to 5-week-old mice [Art−/+ (n = 3), Art−− (n = 7), ArtP70/P70 (n = 5), Art−+/P70 (n = 10)] was amplified in 50 µl of reaction mixture containing set a' primers (10 pmol) (see Supplementary Material). The cycling conditions were: denaturation at 95 °C, 30 cycles of amplification at 95 °C for 15 s, 55 °C for 15 s, 72 °C for 30 s with a 6-s increment per cycle followed by 10 min elongation at 72 °C. The products from the first reaction (5 µl) were used in a nested PCR reaction with the same conditions using primers set b'. The final PCR products (25 µl) were run on a 1.5% agarose gel followed by Southern blotting using probes (primers set c') internal to the primers used for PCR amplification (see Supplementary Material). The second-round PCR products were subcloned into pCR 2.1-TOPO (Invitrogen; Carlsbad, CA, USA) and individual clones were sequenced. TCRβ DB2-to-JB2 intrachromosomal rearrangements were PCR amplified from thymic genomic DNA (100 ng) at an annealing temperature of 62 °C (35 cycles). Each experiment was repeated at least thrice independently.

**Western blot analysis of ATM-dependent responses to IR**

Art+/+, Art−/−, ArtP70/P70 and ATM−/− MEFs (SV40 large T-antigen immortalized) were plated at a density of 3.5 × 106 cells per 10-cm dish then exposed to 10 Gv of γ-rays from a 137Cs source. The cells were allowed to recover for 1 h and then harvested in Laemmli buffer (4% sodium dodecyl sulfate, 20% glycerol, 120 mM Tris–HCl, pH 6.8). Equivalent amounts of whole-cell lysates were resolved on either a 12 or 6% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gel and transferred to polyvinylidene fluoride membrane. Primary antibodies used were: H2AX S139 (1:1000, Millipore; Billerica, MA, USA); pKap1 S824 (1:500, Bethesda Laboratories; Montgomery, TX, USA); pATM S1981 (1:500, Rockland; Gilbertsville, PA, USA). This experiment was repeated thrice independently.

**Co-immunoprecipitation of the MRN complex**

Art+/+ and ArtP70/P70 MEFs were grown to confluency, harvested and then lysed in a buffer containing 25 mM HEPES, pH 7.4, 150 mM KCl, 10 mM MgCl2, 10% glycerol, 2 mM DTT and protease inhibitors (Roche; Basel, Switzerland). Protein concentrations were determined using the Bradford assay. Lysates (6 mg) were pre-cleaned for 1 h with protein G beads (GE Healthcare) at 4 °C, then incubated with α-Mre11 antibody (4.5 μg; Cell Signaling) and protein G beads overnight at 4 °C with constant rotation. The beads were washed twice with lysis buffer followed by two washes in lysis buffer containing 300 mM KCl. The immunoprecipitates were analyzed by 8% SDS–PAGE followed by western blotting with the α-Mre11 (Cell Signaling; Danvers, MA, USA), α-Nbs1 (Novus Biologicals; Littleton, CO, USA) and α-Rad50 (Bethyl Laboratories; Montgomery, TX, USA) antibodies. The protein bands were visualized using IRDye800CW-conjugated goat anti-rabbit secondary antibody (LiCor Biosciences; Lincoln, NE, USA). The co-IPs were repeated thrice independently.

**Hybrid join analysis**

To analyze the levels of coding and hybrid joints between Vκ6–23 and Jκ1, PCR assays were used as described previously (47). Genomic DNA (0.5 μg) isolated from mouse splenocytes for each genotype (ArtP70/P70; n = 4) was PCR amplified in 50 μl with 15 pmol of each primer. PCR conditions were as follows: 95 °C for 5 min followed by 17 cycles of 94 °C (30 s), 64 °C (30 s), 72 °C (30 s). A second PCR reaction was carried out under the same conditions for 25 amplification cycles using 4-fold dilutions of the first PCR reaction and nested primer pairs. The HJ and CJ PCR products were transferred to Zetaprobe membrane and hybridized with pg oligonucleotide. For normalization, 4-fold dilutions starting with 0.5 μg of genomic DNA were PCR amplified. For Vβ14 coding and hybrid joint analysis, genomic DNA (0.5 μg) was isolated from mouse thymocytes for each genotype [ArtP70/P70 (n = 2), Art−/P70 (n = 5)], and PCR analysis was performed as described (47). The PCR products were analyzed by Southern blotting using the pg oligonucleotide as a probe (see Supplementary Material).

**Immunofluorescence analysis of Mre11 foci**

Art+/+, Art−/−, and ArtP70/P70 MEFs (SV40 large T-antigen immortalized) were plated at a density of 2 × 105 cells per well of a 12-well dish and then exposed to 10 Gv of γ-rays from a 137Cs source. Cells were allowed to recover for 8 h and then fixed in 4% paraformaldehyde solution (4% paraformaldehyde, 2% sucrose, pH 7.5) followed by treatment with a permeabilization solution (50 mM NaCl, 3 mM MgCl2, 200 mM sucrose, 10 mM HEPES, pH 7.9, 0.5% Triton X-100), as previously described (82). Fixed cells were incubated for 1 h in phosphate buffered saline (PBST), 0.1% Tween-20 incubated with primary antibody Mre11 (1:500, Cell Signaling; Danvers, MA, USA) and α-Rad50 (Bethyl Laboratories; Montgomery, TX, USA) antibodies. The protein bands were visualized using IRDye800CW-conjugated goat anti-rabbit secondary antibody (LiCor Biosciences; Lincoln, NE, USA). The co-IPs were repeated thrice independently.
Characterization of tumors

All mice were regularly monitored for tumors and analyzed when moribund. Lymphoid tumors were analyzed by flow cytometry with antibodies against surface B-cell (CD43, B220, IgM) and T-cell (CD4, CD8, CD3, TCRβ, CD44, CD25) markers. Thymic and pro-B lymphomas were cultured in RPMI medium 1640 supplemented with 15% fetal calf serum, 25 U/ml IL-2 (BD Biosciences) and 25 ng/ml of IL-7 (PeproTech, Rocky Hill, NJ, USA). The proportion of pro-B and thymic lymphomas in the Art\(^{+/+}\)/p53\(^{-/-}\) cohort was calculated to be statistically significantly different from that observed for Art\(^{-/-}\)/p53\(^{-/-}\) lymphomas (\(P = 0.014\), two-tailed Fisher’s exact test). Data for Art\(^{-/-}\)/p53\(^{-/-}\) tumors also in a mixed 129Sv/C57Bl6 genetic background from a previous publication (54) were included in the calculation (total of 13 lymphomas: 10 pro-B and 3 thymic.)

Chromosomal analyses of tumor metaphases

SKY was performed on metaphases from cells derived from the primary tumor or early passage cultured tumor cells using an interferometer (Applied Spectral Imaging; Vista, CA, USA) and SkyView software. For FISH analyses, early passage tumor cultures were exposed to 100 ng/ml Colcemid for 5.5 h. BAC probes for FISH analysis were obtained from the RPCI-23 library (Children’s Hospital Oakland Research Institute; Oakland, CA, USA) and nick-translated using biotin-11-dUTP or digoxigenin-16-dUTP by standard procedures (Roche; Basel, Switzerland). BAC probes hybridizing to TCR\(^\alpha\)/\(\beta\) are as follows: RPCI-23 204N18 (centromeric to TCR\(\alpha\)/\(\beta\) region) and RPCI-23 269E2 (telomeric to TCR\(\alpha\)/\(\beta\) region). BAC probe hybridizing to TCR\(\beta\) are as follows: RPCI-23 216J19 (spans TRBD1–TRBV31). BAC probe hybridizing to TCR\(\gamma\) are as follows: RPCI-23 212N5 (within TCR\(\gamma\)). BAC probes hybridizing to IgH are as follows: N-myc BAC A-10-1 (54), Bac199 (hybridizes to C\(\alpha\)), Bac 207 (hybridizes to V region). c-myc BAC probe was previously described (83). At least 10 metaphases for each tumor were analyzed by SKY and at least 20 metaphases by FISH.

Southern blot and RT-PCR analyses

Genomic DNA (20 μg) isolated from control tissues (tail or kidney) or Art\(^{+/+}\)/p53\(^{-/-}\) tumor masses was digested with EcoRI. Southern blotting was performed with previously characterized probes hybridizing within the TCR\(\beta\) locus (Drd1), J\(\beta\)1 region, HS3a, C\(\mu\), N-myc and c-myc loci. Southern blots were visualized using a Phosphorimager. Band intensities were quantitated using Image Quant TL v2005 software, and relative levels were normalized to a non-lymphoid locus (LR8). Fold amplification was calculated compared with the intensities of bands in the kidney controls on the same membrane.

Reverse transcription of total RNA (1 μg) isolated from primary Art\(^{+/+}\)/p53\(^{-/-}\) (C219, C263) and Art\(^{-/-}\)/p53\(^{-/-}\) (C405) pro-B lymphomas and wild-type LN was performed using a poly-dT (20) primer and MLV-reverse transcriptase (Invitrogen). PCR amplification of cDNAs was performed using gene-specific primers to c-myc (exons 1 and 3) and N-myc (exons 2 and 3). cDNA levels were normalized to tubulin. Bands were quantitated using AlphaImager 2200 (Alphalnnotec; Santa Clara, CA, USA). RT-PCR reactions were repeated at least four times.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS

We thank Drs David Ferguson and John Moran for helpful discussions.

Conflict of Interest statement. None declared.

FUNDING

This work was supported by NIH grant AI063058 (NIAID), Pew Scholar’s Award (Pew Charitable Trusts), Munn IDEA award (UM Cancer Center) (to J.M.S) and by the NIH UM Cancer Center Support Grant (5 P30 CA46592). C.J. received support from the NIH Genetics Training grant T32-GM07544 (NIGMS). T.M. is a Fullbright Scholar and W.L. received support from the Cellular and Molecular Biology Training Grant (T32-GM07315).

REFERENCES


